business for steady thank serve while you toward becoming you, and In and profitable our clients. continued all a march second our quarter, patients joining we today. Thank continuing us Hoki, the to
control, to of evidence and burn decrease to of pursuit levels. able As projected solid make our non-GAAP our cost in GAAP and higher revenues progress below gross were margins, our cash and we well to continue disciplined quality both
for ongoing in We half lower results. quarters, than have increase in eight revenue, a XXXX cash same consecutive $XXX.X year. forma X% pro burn margins is in the of We and million gross non-GAAP the first period is last which improved year-over-year posted XX% top-line
cancer cancer momentum. forma the health, different revenue solid women's We at pro data, growth digit and pro million hereditary demonstrating double hereditary Looking Despite Sequential X% forma by volume our US continued headwinds up overdue disease business cancer saw growth market, several year-over-year volume payments, for rare commercial disease, lines. of this were in hereditary in which we year-over-year impacted insurance growth quarter. payers both for X% faced terms in rare quarter-over-quarter. the $X and from revenue
possible are with are processing. teams we our payers that ensuring unblock part non-stop, billing Our payment in way every these working to doing
[Technical necessary and are the committing are these comprehensive. We resources Difficulty]
our reimbursement have from better and rare driving in and been women's in have We our health regard. best to recently efforts businesses, used this in successful disease assist those practices
and backlog the overdue all we of high payments reductions half stakeholders of second with of with the seeing are for as urgency XXXX a resolution. We in enter engaging sense are faster
last by where pharma which orders. and be we weaker indicated would we impacted pipeline for also quarter was fee are of our rebuilding lumpy, revenue Oncology service,
leading risk, testing, germline third outcomes at to with the these physicians. in In stronger understanding combination a picture aid pipeline cancer confirm for are patients. Presentations best XXXX better somatic fact, diagnosis, continued Conference Society in Together, cancer highlight quarter. tools of the American and and Oncology seeing the hereditary we selection, treatment for Clinical in to already provides testing, that
Invitae seen increasing as expansions as NCCN in adoption has of oncology, to germline guideline leader this a testing well in generating by as evidence that clinical been effect.
received and usage However, recent even benefits center cancer and diagnosed Radio million did with at are on found who by guideline is endorsing Invitae. Highlighting National expansion presented and [co-authored] in germline Allison hereditary get ASCO, investigators testing them the that for cancer rate community have study underscores suggests the testing, Georgia, XX% oncology worth showcased call our many of All drive burning growth and Public California was testing education underutilization efforts cancer to current front recent is A led it. universal low. elusive Of remains issue of listening confirmation additional one to. and doctor despite and the piece This types. at eligible with this several level. points yet and Kurian the This not guidelines patients not that a germline for patients testing of (ph) Things tumor to hereditary solve and Considered with
patient we million across of second XX% clinical X more of data for mark spectrum quarter, the sharing. diverse the In available areas, reached than which a are
to leading to be clinical highest interpretation scale. well positioned quality at provide of We the continue an industry
half, to resources to in allocate our second ahead growth drive we into and XXXX that will beyond. continue Looking key the areas
basis, million forma Let's million a $XX On with quarter to start oncology oncology. $XX second compared a revenue our was the approximately ago. year pro in
hereditary impacted fee was headwinds payer primarily testing cancer earlier, sales service. in this for for reimbursement said lower I and As and by
represents hereditary are non-genetic is clinics growth settings. patients their to oncology improve opportunity hereditary expert cancer, and our and providers expected receiving cancer cancer and testing and are expansions adoption a better This call are hereditary community the of points underway. testing going for the support forward. further treatment cancer largest physicians facilitate and to majority outcomes among expand of among Efforts In guideline where the usage these
US a in disease oncology our gears volume Switching QX, double-digit we residual non-genetic our had to minimal In expert efforts. channel.
a cost offering and same legacy as efficiency. us differentiated our more XXXX the while in updated updates in from We QX have solution. made plan litigation migration our arising begins improved that solid quality with updating performance progress addresses even We technology, believe technology with primary platform an the also and and matters processes chemistry provide PCM that ongoing streamlined Natera this provides
continue patients in partners importantly, operate, we ability Overall, need offering pharma most continue in and have our PCM and to ability our to of to strong confidence to accurate monitoring.
also business expect delivering times, resources our We we the by our and chemistry have to fee-for-service accelerate complimenting marketing revenue updated faster added. turnaround development
the risk synergies that for diagnosed recent ongoing a between meantime, supports one our on at new meetings active yes, of still physician products. data efforts germline options offerings the considering or Looking at they hereditary been we will of for see Together, comprehensive use presenting of is at germline who individual term, somatic and the oncology we've cancer. most with In medium the testing. anchor
this From cancer of clinical with platform universal study, presentations. management patients cancer had is endorsing breast, we In potential lung ASCO patients what of patients separate history pathogenic in this This undergoing which to germline positive germline study colorectal with meeting in lung have cancer implications. variant testing germline no June, have two ovarian, personal with seen of similar family year's cancer, all guidelines testing. and prevalence pancreatic, XX% was or with focus of the of
continue testing. the they universal to of support clinicians do pursue make benefits investment as germline We the the and work,
in performance In neuro and driven we strong by approximately genetics. the line, both panels, business pediatric rare cardio well QX forma of year-over-year, saw as in XX% disease as significant pro revenue
improved We XX% margins rates to up expanded and continue a disorders testing gross approximately and improve panel of offerings seeing implemented forma In QX. on broaden NDD in year-over-year in health, pro number an launched are a basis. reimbursement or was neurodevelopmental also our to We've category. women's this programs revenue
screening received our well Our panel is growing and continues base. by customer carrier to perform well
share increasing along with sales market productivity We gains. are our seeing team, with
biopharma side, understanding to Invitae’s introduce patient and the partners prescription to precise enable with population. as such more deliver we the therapy to more clinical, data researchers the claims continue to On their deepen patient a journey effective products data most new of data ultimately and genetic linking and
expand We've also improvements margins. and working cycle flow achieved other partnerships areas have to through revenue steady insights specific partners in which genetic capital, of data cash We bolster to products, their and interest. to our helped continue which provide and gross
exit that while exploring made is best solely PGX strategic related assets. the our to lab and for to testing the business Finally, dedicated the close the path pharmacogenomics Seattle decision we
be While care, limited are time half expand patient we impact on The and investment fully have approximately believe a XXXX is we full second our impact accretive will although desired to future further reimbursement in to of that PGX the and to its expected million, be decided resource to $X consistent gross the it year utility horizon. within margins. efforts path revenue our and on
turn Hoki will And to the to discuss financials. call the with back I that,
